Predicted sensitivity to endocrine therapy for stage II-III hormone receptor-positive and HER2-negative (HR+/HER2−) breast cancer before chemo-endocrine therapy

Annals of Oncology - Tập 32 - Trang 642-651 - 2021
L. Du1, C. Yau2, L. Brown-Swigart3, R. Gould1, G. Krings3, G.L. Hirst2, I. Bedrosian4, R.M. Layman5, J.M. Carter6, M. Klein7, S. Venters2, S. Shad2, M. van der Noordaa2, A.J. Chien8, T. Haddad9, C. Isaacs10, L. Pusztai11, K. Albain12, R. Nanda13, D. Tripathy5
1Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, USA
2Department of Surgery, University of California, San Francisco, USA
3Department of Pathology, University of California, San Francisco, USA
4Department of Breast Surgery, The University of Texas MD Anderson Cancer Center, Houston, USA
5Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA
6Department of Pathology, Mayo Clinic, Rochester, USA
7Department of Pathology, University of Minnesota, Minneapolis, USA
8Department of Medicine, University of California, San Francisco, USA
9Department of Medicine, Mayo Clinic, Rochester, USA
10Department of Medicine,, Georgetown University,, Washington, USA
11Department of Medicine, Yale University School of Medicine, New Haven, USA
12Department of Medicine, Loyola University, Chicago, USA
13Department of Medicine, University of Chicago, Chicago, USA

Tài liệu tham khảo